Top

Published in:

Open Access 01-12-2021 | Tirofiban | Research article

Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke

Authors: Chunrong Tao, Yuyou Zhu, Chao Zhang, Jianlong Song, Tianlong Liu, Xiaodong Yuan, Wenwu Luo, Changchun Chen, Dezhi Liu, Yuanyuan Zhu, Jie Liu, Wei Hu

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

Studies have suggested that glycoprotein IIb/IIIa antagonists such as tirofiban are beneficial for patients with acute coronary syndromes. However, it is still uncertain about the efficacy and safety of tirofiban in patients with acute ischemic stroke (AIS).

Methods

In this prospective non-randomized study, 255 AIS patients were recruited from 4 comprehensive stroke centers in China between January, 2017 and May, 2018. Among them,169 patients were treated with aspirin plus clopidogrel and 86 patients were treated with tirofiban. The primary functional outcome was the distribution of the 90 days’ modified Rankin Scale (mRS). The safety outcomes included the incidence of intracranial hemorrhage (ICH) at discharge and mortality at 3 months.

Results

In the propensity score matched cohort, tirofiban alone was noninferior to the dual antiplatelet with regard to the primary outcome (adjusted common odds ratio, 0.97; 95% confidence interval, 0.46 to 2.04; P = 0.93). Mortality at 90 days was 10% in the dual antiplatelet group and 8% in the tirofiban group (adjusted odds ratio 0.75; 95% CI 0.08 to 7.40, p = 0.81). There was no difference of the ICH rate between two groups (adjusted odds ratio 0.44; 95% CI 0.13 to 1.48, p = 0.18). In the inverse probability of treatment weighting-propensity score-adjusted cohort, similar differences were found for functional and safety outcomes.

Conclusions

Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found.

Trial registration

Chinese clinical trial registry, ChiCTR2000034443, 05/07/2020. Retrospectively registered.

Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2016;387(10015):251–72.CrossRef

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early Management of Patients with Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early Management of Acute Ischemic Stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–418. https://doi.org/10.1161/STR.0000000000000211.CrossRefPubMed

Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (London, England). 2007;369(9558):275–82.CrossRef

Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236.

Li W, Lin L, Zhang M, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke. 2016;47(10):2649–51.

Rognoni A, Lupi A, Secco GG, et al. Update on glycoprotein IIb/IIIa: role in primary coronary intervention. Cardiovasc Hematol Agents Med Chem. 2011;9(2):106–12.CrossRef

Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 2014(3):CD005208.

Cheng Z, Geng X, Gao J, et al. Intravenous administration of standard dose tirofiban after mechanical arterial recanalization is safe and relatively effective in acute ischemic stroke. Aging Dis. 2019;10(5):1049–57.

Kellert L, Hametner C, Rohde S, et al. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. 2013;44(5):1453–5. https://doi.org/10.1161/STROKEAHA.111.000502.

10.

Pan X, Zheng D, Zheng Y, et al. Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke. 2019;26(8):1105–10. https://doi.org/10.1007/s00234-019-02282-1.

11.

Junghans U, Seitz RJ, Aulich A, Freund HJ, Siebler M. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis (Basel, Switzerland). 2001;12(4):308–12.CrossRef

12.

Torgano G, Zecca B, Monzani V, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. Cerebrovasc Dis (Basel, Switzerland). 2010;29(3):275–81.CrossRef

13.

Siebler M, Hennerici MG, Schneider D, et al. Safety of Tirofiban in acute ischemic stroke: the SaTIS trial. Stroke. 2011;42(9):2388–92.CrossRef

14.

Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (London, England). 1998;352(9136):1245–51.CrossRef

15.

Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387–98. https://doi.org/10.1016/S0895-4356(00)00321-8.CrossRefPubMed

16.

Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–34. https://doi.org/10.1080/03610910902859574.CrossRef

17.

Austin P. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107. https://doi.org/10.1002/sim.3697.CrossRefPubMedPubMedCentral

18.

Austin P. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424. https://doi.org/10.1080/00273171.2011.568786.CrossRef

19.

Austin P. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057–69. https://doi.org/10.1002/sim.6004.CrossRefPubMed

20.

Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–61. https://doi.org/10.1002/pst.433.CrossRefPubMed

21.

Cattaneo MD. Efficient semiparametric estimation of multi-valued treatment effects under ignorability. J Econ. 2010;155(2):138–54. https://doi.org/10.1016/j.jeconom.2009.09.023.CrossRef

22.

Gong J, Shang J, Yu H, et al. Tirofiban for acute ischemic stroke: systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(4):475–81.CrossRef

23.

Yang M, Huo X, Gao F, Wang A, Ma N, Shi H, et al. Low-dose rescue tirofiban in mechanical thrombectomy for acute cerebral large-artery occlusion. Eur J Neurol. 2020;27(6):1056–61. https://doi.org/10.1111/ene.14170.CrossRefPubMed

24.

Zhang Y, Zhang QQ, Fu C, Wang L, Zhang GQ, Cao PW, et al. Clinical efficacy of tirofiban combined with a solitaire stent in treating acute ischemic stroke. Braz J Med Biol Res. 2019;52(10):e8396. https://doi.org/10.1590/1414-431x20198396.CrossRefPubMedPubMedCentral

25.

Yi HJ, Sung JH, Lee DH. Safety and efficacy of intra-arterial Tirofiban injection during mechanical Thrombectomy for large artery occlusion. Curr Neurovasc Res. 2019;16(5):416–24. https://doi.org/10.2174/1567202616666191023154956.CrossRefPubMed

26.

Sun C, Li X, Zhao Z, Chen X, Huang C, Li X, et al. Safety and efficacy of Tirofiban combined with mechanical Thrombectomy depend on ischemic stroke etiology. Front Neurol. 2019;10:1100. https://doi.org/10.3389/fneur.2019.01100.CrossRefPubMedPubMedCentral

27.

Quan T, Hou H, Xue W, Yu G, Ma H, Sun J, et al. Endovascular treatment of acute intracranial vertebrobasilar artery occlusion: a multicenter retrospective observational study. Neuroradiology. 2019;61(12):1477–84. https://doi.org/10.1007/s00234-019-02282-1.CrossRefPubMed

28.

Yu T, Lin Y, Jin A, Zhang P, Zhou X, Fang M, et al. Safety and efficiency of low dose intra-arterial Tirofiban in mechanical Thrombectomy during acute ischemic stroke. Curr Neurovasc Res. 2018;15(2):145–50. https://doi.org/10.2174/1567202615666180605104931.CrossRefPubMed

29.

Zhao W, Che R, Shang S, Wu C, Li C, Wu L, et al. Low-dose Tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular Thrombectomy. Stroke. 2017;48(12):3289–94. https://doi.org/10.1161/STROKEAHA.117.019193.CrossRefPubMed

30.

Luo Y, Yang Y, Xie Y, Yuan Z, Li X, Li J. Therapeutic effect of pre-operative tirofiban on patients with acute ischemic stroke with mechanical thrombectomy within 6-24 hours. Interv Neuroradiol. 2019;25(6):705–9. https://doi.org/10.1177/1591019919851167.CrossRefPubMedPubMedCentral

31.

Liu J, Shi Q, Sun Y, et al. Efficacy of Tirofiban administered at different time points after intravenous thrombolytic therapy with Alteplase in patients with acute ischemic stroke. J Stroke Cerebrovascr Dis. 2019;28(4):1126–32.CrossRef

32.

Wu C, Sun C, Wang L, et al. Low-dose Tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis. Stroke. 2019;50(12):3481–7.CrossRef

33.

Ma Q, Ma Y, Wang X, et al. Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study. Int J Cardiovasc Imaging. 2020;36(6):1121–32.

Title: Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke
Authors: Chunrong Tao
Yuyou Zhu
Chao Zhang
Jianlong Song
Tianlong Liu
Xiaodong Yuan
Wenwu Luo
Changchun Chen
Dezhi Liu
Yuanyuan Zhu
Jie Liu
Wei Hu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Tirofiban
Stroke
Clopidogrel
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02268-8

2024 ASCO Annual Meeting

Springer Medicine

Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke

Abstract

Background

Methods

Results

Conclusions

Trial registration

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis

Next-generation sequencing combined with serological tests based pathogen analysis for a neurocysticercosis patient with a 20-year history:a case report

Shifting of global aphasia to Wernicke’s aphasia in a patient with intact motor function: a case report

Acute recurrent rhabdomyolysis in a Chinese boy associated with a novel compound heterozygous LPIN1 variant: a case report

Expression of and correlational patterns among neuroinflammatory, neuropeptide, and neuroendocrine molecules from cerebrospinal fluid in cerebral palsy

Prevalence and associated factors of premature discontinuation of antiplatelet therapy after ischemic stroke: a nationwide population-based study